Overview


According to FutureWise analysis the market for advanced drug delivery systems in 2023 is US$ 327.8 billion, and is expected to reach US$ 492.49 billion by 2031 at a CAGR of 5.2%.

The process of providing a pharmaceutical substance to have therapeutic effects on individuals or animals is known as drug delivery. A drug's compliance, safety, and efficacy can all be significantly enhanced by transforming it from its traditional form into a unique delivery system. An old drug molecule can be given new life using an advanced drug delivery system (ADDS). Various technological advances in unit operations such as drying, filtration, and mixing also help to advancement in modification and improvement in formulations. With the right design, an ADDS can be a game-changer for addressing issues connected with targeted drug delivery. Pharmaceutical companies have been working on innovative drug delivery systems due to the growing demand for safer, more effective methods of administering drugs to patients.

Drug delivery technologies improve treatment outcomes in many ways, including enhancing therapeutic efficacy, reducing toxicity, increasing patient compliance, and enabling entirely new medical treatments. As the therapeutic landscape has evolved from small-molecule drugs to a new generation of therapeutics, including proteins, peptides, monoclonal antibodies, nucleic acids, and even live cells, drug delivery technologies have evolved to meet their unique delivery needs.

FutureWise Market Research has published a report that provides an insightful analysis advanced drug delivery system market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, advanced drug delivery system market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  •  3M Company
  •  Abbott Laboratories
  •  Amgen Inc.
  •  Astrazeneca Plc
  •  Baxter International
  •  Bayer AG
  •  Boston Scientific Corporation
  •  Becton, Dickinson and Company
  •  Johnson and Johnson
  •  Pfizer Inc.
  •  Novartis AG
  •  Allergan
  •  Genentech, Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Advanced Drug Delivery System Market:

  • In March 2022, Corium, Inc. received US Food and Drug Administration approval for Corium's ADLARIY as a treatment for patients with mild, moderate, and severe dementia of Alzheimer's type. ADLARITY is one of the foremost and only once-weekly patches to deliver consistent doses of donepezil through the skin continuously.

  • In March 2022, the United States FDA approved the first generic of Symbicort Inhalation Aerosol for the treatment of two common pulmonary health illnesses: asthma in patients six years of age and older and chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.

The growing prevalence of advanced drug delivery systems, such as thin film drugs, is expected to boost the market during the forecast period attributed to their various drivers in the pharmaceutical industry. These include their potential to enhance patient adherence due to ease of administration, convenience, and pleasant taste, leading to improved treatment adherence. Oral thin-film drugs also offer rapid drug dissolution and absorption, allowing for faster onset of action and improved bioavailability, leading to more efficient and effective therapeutic outcomes. Furthermore, these delivery systems enable precise dosing and controlled release, enhancing therapeutic efficacy and minimizing potential side effects. For instance, in June 2021, Shilpa Medicare Ltd. introduced an oral thin film formulation, a pediatric dose of paracetamol oral thin film, under the brand name Molshil. Shilpa approved Molshil oral thin films after sufficiently complying with bioequivalence requirements. Shilpa's Paracetamol oral thin films are patent-protected and are the first of their type in the world. Furthermore, the rise in drug recalls and failures may obstruct the growth of the advanced drug delivery system market. The complexity involved in developing and manufacturing these innovative drug delivery technologies may increase the likelihood of unexpected issues arising during production. Drug recalls, driven by quality control issues, stability problems, or side effects, may result in substantial financial loss and damage to pharmaceutical companies. Additionally, the failure of some advanced drug delivery products to meet efficacy and safety standards during clinical trials may lead to regulatory hurdles and delays in market approvals.

By Type

  •  Oral Drug Delivery System
  •  Injection-based Drug Delivery System
  •  Inhalation/Pulmonary Drug Delivery System
  •  Transdermal Drug Delivery System
  •  Trans mucosal Drug Delivery System
  •  Carrier-based Drug Delivery System
  •  Other Types

By Application

  •  Cardiovascular Diseases
  •  Oncology
  •  Urology
  •  Diabetes
  •  CNS
  •  Ophthalmology
  •  Infections
  •  Other Applications

By Technology

  •  Prodrug
  •  Implants and Intrauterine Devices
  •  Targeted Drug Delivery
  •  Polymeric Drug Delivery
  •  Other Technologies

By Region

  •  North America
  •  Europe
  •  Asia-Pacific
  •  Latin America
  •  Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Owing to the adoption of improved drug delivery solutions, follow-up of advanced treatments in healthcare, the growing preference toward self-administration of drugs, increasing innovations in injectable drug delivery systems, the increased adoption rate of new healthcare technologies, and the increasing prevalence of chronic conditions are the primary drivers for the U.S. target market. Moreover, rising heart condition is a leading cause of death that burdens individuals, communities, healthcare providers, and systems in the region. Nearly 50% of adults in the U.S. have some form of cardiovascular disease. According to the American Cancer Society, around 2 million new cancer cases are foreseen to be diagnosed, and around 609,000 individuals will die from cancer in the United States in 2022. Therefore, the above-mentioned factors are anticipated to propel the market growth in the area.

  •  Tier 1 players- established companies in the market with a major market share
  •  Tier 2 players
  •  Emerging players which are growing rapidly
  •  New Entrants

  •  Growth prospects
  •  SWOT analysis
  •  Key trends
  •  Key data-points affecting market growth

  •  To provide with an exhaustive analysis on the Advanced Drug Delivery Systems Market By Type, By Application, By Technology and By Region.
  •  To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  •  To evaluate and forecast micro-markets and the overall market
  •  To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  •  To record and evaluate competitive landscape mapping- Type launches, technological advancements, mergers and expansions

  •  We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  •  The customization Mobility Care offered are free of charge with purchase of any license of the report
  •  You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Advanced Drug Delivery Systems Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Advanced Drug Delivery Systems Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Advanced Drug Delivery Systems Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Advanced Drug Delivery Systems Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Oral Drug Delivery System
        2. Injection-based Drug Delivery System
        3. Inhalation/Pulmonary Drug Delivery System
        4. Transdermal Drug Delivery System
        5. Trans mucosal Drug Delivery System
        6. Carrier-based Drug Delivery System
        7. Other Types

  • 8.   Advanced Drug Delivery Systems Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Cardiovascular Diseases
        2. Oncology
        3. Urology
        4. Diabetes
        5. CNS
        6. Ophthalmology
        7. Infections
        8. Other Applications

  • 9.   Advanced Drug Delivery Systems Market, By Technology Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Prodrug
        2. Implants and Intrauterine Devices
        3. Targeted Drug Delivery
        4. Polymeric Drug Delivery
        5. Other Technologies

  • 10.   North America Advanced Drug Delivery Systems Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Advanced Drug Delivery Systems Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Advanced Drug Delivery Systems Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Advanced Drug Delivery Systems Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Types Offered and Financial Layouts)

    •   1. 3M Company
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Abbott Laboratories
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Amgen Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Astrazeneca Plc
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Baxter International
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Bayer AG
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Boston Scientific Corporation
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Becton, Dickinson and Company
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Johnson and Johnson
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
          10. Pfizer Inc.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
          11. Novartis AG
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
          12. Allergan
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
          13. Genentech, Inc.
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11